A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies (NCT00649584)
This study will examine the safety profile of brentuximab vedotin (also known as SGN-35) alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.
This trial is sponsored by Seattle Genetics. 
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Anaplastic Large-Cell Lymphoma
- Phase: I
- Enrollment: 44
- Start: March 2008
- Completion: February 2010
- Last verified: December 2014
Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.